Erschienen in:
22.06.2016 | Original Scientific Report
Kidney Transplant Outcomes in the Super Obese: A National Study From the UNOS Dataset
verfasst von:
Pooja Kanthawar, Xiaonan Mei, Michael F. Daily, Jyotin Chandarana, Malay Shah, Jonathan Berger, Ana Lia Castellanos, Francesc Marti, Roberto Gedaly
Erschienen in:
World Journal of Surgery
|
Ausgabe 11/2016
Einloggen, um Zugang zu erhalten
Abstract
Background
We evaluated outcomes of super-obese patients (BMI > 50) undergoing kidney transplantation in the US.
Methods
We performed a review of 190 super-obese patients undergoing kidney transplantation from 1988 through 2013 using the UNOS dataset.
Results
Super-obese patients had a mean age of 45.7 years (21–75 years) and 111 (58.4 %) were female. The mean BMI of the super-obese group was 56 (range 50.0–74.2). A subgroup analysis demonstrated that patients with BMI > 50 had worse survival compared to any other BMI class. The 30-day perioperative mortality and length of stay was 3.7 % and 10.09 days compared to 0.8 % and 7.34 days in nonsuper-obese group. On multivariable analysis, BMI > 50 was an independent predictor of 30-day mortality, with a 4.6-fold increased risk of perioperative death. BMI > 50 increased the risk of delayed graft function and the length of stay by twofold. The multivariable analysis of survival showed a 78 % increased risk of death in this group. Overall patient survival for super-obese transplant recipients at 1, 3, and 5 years was 88, 82, and 76 %, compared to 96, 91, 86 % on patients transplanted with BMI < 50. A propensity score adjusted analysis further demonstrates significant worse survival rates in super-obese patients undergoing kidney transplantation.
Conclusion
Super-obese patients had prolonged LOS and worse DGF rates. Perioperative mortality was increased 4.6-fold compared to patients with BMI < 50. In a subgroup analysis, super-obese patients who underwent kidney transplantation had significantly worse graft and patient survival compared to underweight, normal weight, and obesity class I, II, and III (BMI 40–50) patients.